| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On Monday, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) and Bilthoven Biologicals collaborated to advance TNX-801, Tonix’s mpox vaccine candidate.
Bilthoven Biologicals is part of the world’s largest vaccine manufacturer, the Cyrus Poonawalla Group, which includes the Serum Institute of India.
Also Read: Nano-Cap Tonix Pharmaceuticals Secures Large US Department of Defense Contract.
TNX-801 (recombinant horsepox virus) is a live replicating, attenuated virus vaccine based on horsepox in preclinical development to prevent mpox and smallpox.
TNX-801 is based on technology that has the potential to be used as a viral vector platform from which recombinant versions can be developed to protect against other infectious diseases.
Bilthoven Biologicals is a global vaccine company that produces prophylactic and therapeutic use vaccines.
The European Union has selected Bilthoven Biologicals for its pandemic preparedness program of ‘ever warm’ vaccine manufacturing companies.
TNX-801 has demonstrated in animal models to provide immune protection with better tolerability than vaccines based on 20th-century vaccinia viruses.
Preclinical studies have shown positive efficacy data, demonstrating that TNX-801 protected non-human primates against lethal challenges with intratracheal Clade 1 mpox virus.
After a single dose vaccination, TNX-801 prevented clinical disease and lesions and decreased shedding in the mouth and lungs of non-human primates.
These findings are consistent with mucosal immunity and suggest the ability to block forward transmission.
On August 14, 2024, the World Health Organization determined that the upsurge of mpox in many African countries constitutes a public health emergency of international concern, the second such declaration in the past two years called in response to an mpox outbreak.
Price Action: TNXP stock was up 9.76% to $0.37 at the last check on Monday.
Read Next:
Image via Centers for Disease Control and Prevention
Posted In: TNXP
